IMNPQ Projected Dividend Yield
Immune Pharmaceuticals Inc ( OTCBB : IMNPQ )Immune Pharmaceuticals is a clinical stage biopharmaceutical company focusing on the development of targeted therapeutics in the fields of immunology, inflammation, dermatology and oncology. Co.'s primary product candidate, bertilimumab, is a human monoclonal antibody, which targets eotaxin-1, a chemokine and has potential applications as a treatment for a variety of allergic and inflammatory diseases. Ceplene (histamine dihydrochloride), Co.'s primary oncology product candidate, is a small molecule, targeting the Histamine-2 Receptor, to be used in conjunction with low dose Interluken-2 to overcome immunosuppression in acute myeloid leukemia and potentially other malignancies. 20 YEAR PERFORMANCE RESULTS |
IMNPQ Dividend History Detail IMNPQ Dividend News IMNPQ Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |